Caption Management 13F: Adds $7.4M to AVTX Stake

Caption Management Expands Avalo Holdings

Caption Management significantly grew its investment in Avalo Therapeutics, Inc. (AVTX) on NasdaqCM, according to a recent Form 13F filing with the SEC for the period ending May 15, 2026. The fund added 402,359 shares, which translates to a 764.3% increase from its previous holding of 52,641 shares. This expansion brings the total position to 455,000 shares with an estimated reported value of $8.41 million. Because 13F filings look backward at past quarters, this snapshot reflects holdings at that specific date and may not represent the fund's current position today.

Avalo Therapeutics Stock Performance

Avalo Therapeutics shares trade around $18.48, sitting comfortably between its 52-week low of $10.70 and its 52-week high of $24.27. The stock's 50-day moving average rests at $18.70, while its 200-day moving average sits at $16.87. The company holds a market capitalization of $867.20 million and features a current ratio of 19.31 alongside a debt-to-equity ratio of 0.05, pointing to a liquid balance sheet.

Recent Insider Activity at Avalo

Insiders have also been active in company stock recently. On June 23, 2026, Chief Medical Officer Mittie Doyle purchased 1,450 shares at an average price of $8.04, totaling $11,658. On that same date, Ron Philip also acquired 40,200 shares in a transaction valued at zero dollars.

Analysts Set New Price Targets

Wall Street analysts maintain a generally positive outlook on the stock. On August 7, 2026, Guggenheim maintained its Buy rating while lowering its price target from $50.00 to $48.00. On the same day, HC Wainwright & Co. also kept a Buy rating while trimming its target from $35.00 to $30.00. Earlier, on July 6, 2026, Leerink Partners initiated coverage with an Outperform rating and a $38.00 price target. Overall, the company carries a consensus recommendation key of strong_buy with a mean target price of $44.08 across 12 analyst opinions.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company headquartered in Wayne, Pennsylvania. The firm focuses on developing interleukin-1 beta-based treatments for immune-mediated inflammatory diseases in the United States. Its primary candidate is AVTX-009, a humanized monoclonal antibody currently evaluated in phase 2 clinical trials. The company employs a lean team of 33 people to advance its pipeline.

What to Watch at Avalo Therapeutics, Inc.

Investors tracking Avalo Therapeutics should keep an eye on upcoming pipeline updates and clinical trial results for its lead antibody candidate. The company's next scheduled earnings report is expected around November 12, 2026. As always, institutional filing data remains historical and subject to change in subsequent quarterly reports.